Skip to main content
A Singapore Government Agency Website

Good Manufacturing Practice and Good Distribution Practice Standards

Establish a quality system that ensures your products are properly handled, stored and distributed to assure quality and integrity throughout the supply chain.

Good Manufacturing Practice Standard

Good Manufacturing Practice Standard

Good Manufacturing Practice (GMP) is a vital component of Quality Assurance to help ensure that therapeutic products and Chinese Proprietary Medicines (CPM) are consistently produced with the quality standards appropriate for their intended use. All manufacturers, including assemblers of therapeutic products and CPM intended for the Singapore market, are required to conform to the GMP standard.

As a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), we adopt the PIC/S Guide to GMP for Medicinal Products (Part I) and its relevant annexes as our current GMP standards. Our GMP auditors will conduct audits on local manufacturers of therapeutic product and CPM for compliance with these GMP standards.

Trending of common deficiencies raised for GMP inspections conducted

Year   
 2019 Trending of GMP Deficiencies in 2019513 KB
 2020  Trending of GMP Deficiencies in 20201096 KB
 2021  Trending of GMP Deficiencies in 20211129 KB

  

Good Distribution Practice Standard

Good Distribution Practice Standard

Good Distribution Practice (GDP) is a vital component of Quality Assurance. It requires the company to establish a quality system which ensures that products are consistently stored and handled under appropriate conditions as required by the marketing authorisation or product specification.

Compliance to our Guidance Notes on Good Distribution Practice263 KB is mandatory for all local importers and wholesalers of Therapeutic Products and Chinese Proprietary Medicines intended for the Singapore market. Our GDP auditors will conduct audits on companies in accordance with these GDP standards prior to the issuance of local dealer’s licences.

Note: Our Guidance Notes on Good Distribution Practice is revised on 01 March 2021 to primarily include additional GDP requirements for Cell, Tissue and Gene Therapy Products (CTGTP). Please refer to the Guidance Notes on Good Distribution Practice (with Tracked Changes) 234 KB on the changes made on the latest version. Underline denotes addition while strike-through denotes deletion.

Trending of common deficiencies raised for GDP inspections conducted

Year
2019 Trending of GDP Deficiencies in 2019803 KB
2020 Trending of GDP Deficiencies in 2020800 KB
2021 Trending of GDP Deficiencies in 2021283 KB
Share